Latest Regulatory Updates News

DroneShield Limited has retracted its recent announcement of $7.6 million in new U.S. Government orders, clarifying these were reissued contracts rather than fresh deals. The company is addressing the administrative error to prevent future confusion.

Aguia Resources advances its phosphate operations in Brazil with new funding and plant upgrades, while a management overhaul in Colombia reveals a significant gold discovery at Santa Barbara.

Dome Gold Mines reports steady progress on its Sigatoka heavy mineral sands project despite delays in a government-led river desilting program, while exploring funding options for its Nadrau copper-gold project in Fiji.

Neuren Pharmaceuticals has secured FDA Fast Track designation for its drug NNZ-2591 targeting Phelan-McDermid syndrome, accelerating its path through clinical development. This milestone underscores the urgent need for treatments in rare neurodevelopmental disorders.

Challenger Limited reported a solid 4% increase in total Life sales to $2.5 billion in Q1 FY26, buoyed by strong annuity sales and strategic partnerships. The company reaffirmed its FY26 earnings guidance while highlighting upcoming regulatory changes expected to benefit the sector.

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

St Barbara Limited has secured approximately A$58 million through an institutional placement to fund its Simberi Expansion Project and advance the 15-Mile Processing Hub in Nova Scotia. This capital raise supports the company’s growth ambitions amid ongoing regulatory and operational developments.

Vanguard Investments Australia has announced the estimated distribution and tax components for its Vanguard FTSE Asia ex Japan Shares Index ETF for the quarter ending September 2025, highlighting key details for investors on cash payouts and tax implications.

Infinity Metals has submitted key documentation for its San José Lithium Project mining licence in Spain, moving closer to public consultation despite delays. The company also announces executive role changes to streamline costs amid a softer lithium market.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

VGI Partners Global Investments has completed its on-market share purchases under the Dividend Reinvestment Plan, updating investors with a new Appendix 3A.1 filing.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.